Microbot Medical Inc IPO prospectus (version 2026-04-10)

Up to $39,230,691 of Common Stock We have entered into an At The Market Offering Agreement, or sales agreement, with H.C. Wainwright & Co., LLC, orWainwright, dated June 10, 2021, as amended on July 1, 2024, relating to the sale of shares of our common stock offered by thisprospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell Our common stock is listed on The Nasdaq Capital Market under the symbol “MBOT”. On April 8, 2026, the last reported saleprice of our common stock on The Nasdaq Capital Market was $2.35 per share. Upon our delivery of a placement notice and subject to the terms and conditions of the sales agreement, Wainwright may sellshares of our common stock, if any, under this prospectus supplement and the accompanying prospectus by any method permitted thatis deemed an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act,including sales made directly on or through the Nasdaq Capital Market, the existing trading market for our common stock, sales madeto or through a market maker other than on an exchange or otherwise, directly to Wainwright as principal, in negotiated transactions atmarket prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or in any other method permittedby law. If we sell shares of common stock to Wainwright, as principal, we will enter into a separate terms agreement with Wainwright, We will pay Wainwright a commission of 3.0% of the gross proceeds of the sales price per share sold. In connection with the saleof common stock on our behalf pursuant to this prospectus supplement and the accompanying prospectus, Wainwright will be deemedto be an “underwriter” within the meaning of the Securities Act and the compensation of Wainwright will be deemed to be Investing in our common stock involves certain risks. See “Risk Factors” beginning on page S-7 of this prospectussupplement and page 6 of the accompanying base prospectus and the risks and uncertainties described in the documents wefile with the Securities and Exchange Commission that are incorporated by reference in this prospectus supplement for certain Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthesesecurities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying base prospectus. H.C. Wainwright & Co. The date of this prospectus supplement is April 10, 2026. PROSPECTUS SUPPLEMENTPAGEABOUT THIS PROSPECTUS SUPPLEMENTS-1SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTSS-2PROSPECTUS SUPPLEMENT SUMMARYS-3THE OFFERINGS-5RISK FACTORSS-7USE OF PROCEEDSS-9DILUTIONS-10PLAN OF DISTRIBUTIONS-12LEGAL MATTERSS-13EXPERTSS-13WHERE YOU CAN FIND ADDITIONAL INFORMATIONS-13INCORPORATION OF CERTAIN INFORMATION BY REFERENCES-14PROSPECTUSPagesPROSPECTUS SUMMARY1RISK FACTORS6CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS6USE OF PROCEEDS7PLAN OF DISTRIBUTION7DESCRIPTION OF COMMON STOCK9DESCRIPTION OF PREFERRED STOCK10DESCRIPTION OF WARRANTS11DESCRIPTION OF DEBT SECURITIES13DESCRIPTION OF RIGHTS18DESCRIPTION OF UNITS20LEGAL MATTERS23EXPERTS23WHERE YOU CAN FIND MORE INFORMATION23INCORPORATION OF CERTAIN INFORMATION BY REFERENCE24S-i ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement relates to the offering of our common stock. Before buying any of the common stock that we areoffering, you should carefully read the accompanying base prospectus, this prospectus supplement, any supplement to this prospectussupplement, the information and documents incorporated herein by reference and the additional information under the heading “Where We provide information to you about this offering of our common stock in two separate documents that are bound together: (i)this prospectus supplement, which describes the specific details regarding this offering; and (ii) the accompanying base prospectus,which provides general information, some of which may not apply to this offering. Generally, when we refer to this “prospectus,” weare referring to both documents combined. If information in this prospectus supplement is inconsistent with the accompanying baseprospectus, you should rely on this prospectus supplement. To the extent there is a conflict between the information contained in thisprospectus supplement, on the one hand, and the information contained in any document incorporated by reference in this prospectus You should rely only on this prospectus supplement and the information incorporated or deemed to be incorporated by referencein this prospectus supplement or in any free writing prospectuses we provide you. We have not, and Wainwright has not, authorizedanyone to provide you with information that is in addition to, or different from, that contained or incorporated by reference in thisprospectus supplement. If anyone provides you with different or inc